Next Article in Journal
Nrf2, the Master Regulator of Anti-Oxidative Responses
Next Article in Special Issue
BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
Previous Article in Journal
High-Throughput RNA-Seq Data Analysis of the Single Nucleotide Polymorphisms (SNPs) and Zygomorphic Flower Development in Pea (Pisum sativum L.)
Previous Article in Special Issue
Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia
Article

Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma

1
Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
2
Department of Physiology and Neuroscience, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(12), 2773; https://doi.org/10.3390/ijms18122773
Received: 28 November 2017 / Revised: 14 December 2017 / Accepted: 15 December 2017 / Published: 20 December 2017
(This article belongs to the Special Issue Chimeric Antigen Receptor (CAR) T Cell Therapy)
T cells expressing chimeric antigen receptors (CARs) recognizing CD19 epitopes have produced remarkable anti-tumor effects in patients with B-cell malignancies. However, cancer cells lacking recognized epitopes can emerge, leading to relapse and death. Thus, CAR T cells targeting different epitopes on different antigens could improve immunotherapy. The Lym-1 antibody targets a conformational epitope of Human Leukocyte Antigen-antigen D Related (HLA-DR) on the surface of human B-cell lymphomas. Lym-1 CAR T cells were thus generated for evaluation of cytotoxic activity towards lymphoma cells in vitro and in vivo. Human T cells from healthy donors were transduced to express a Lym-1 CAR, and assessed for epitope-driven function in culture and towards Raji xenografts in NOD-scidIL2Rgammanull (NSG) mice. Lym-1 CAR T cells exhibited epitope-driven activation and lytic function against human B-cell lymphoma cell lines in culture and mediated complete regression of Raji/Luciferase-Green fluorescent protein (Raji/Luc-GFP) in NSG mice with similar or better reactivity than CD19 CAR T cells. Lym-1 CAR transduction of T cells is a promising immunotherapy for patients with Lym-1 epitope positive B-cell malignancies. View Full-Text
Keywords: cancer immunotherapy; lymphoma; CAR T cells; Lym-1 cancer immunotherapy; lymphoma; CAR T cells; Lym-1
Show Figures

Graphical abstract

MDPI and ACS Style

Zheng, L.; Hu, P.; Wolfe, B.; Gonsalves, C.; Ren, L.; Khawli, L.A.; Kaslow, H.R.; Epstein, A.L. Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma. Int. J. Mol. Sci. 2017, 18, 2773. https://doi.org/10.3390/ijms18122773

AMA Style

Zheng L, Hu P, Wolfe B, Gonsalves C, Ren L, Khawli LA, Kaslow HR, Epstein AL. Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma. International Journal of Molecular Sciences. 2017; 18(12):2773. https://doi.org/10.3390/ijms18122773

Chicago/Turabian Style

Zheng, Long, Peisheng Hu, Brandon Wolfe, Caryn Gonsalves, Luqing Ren, Leslie A. Khawli, Harvey R. Kaslow, and Alan L. Epstein 2017. "Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma" International Journal of Molecular Sciences 18, no. 12: 2773. https://doi.org/10.3390/ijms18122773

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop